, with the lowest incidence being reported in Japan and Israel [2] . These great ranges may reflect racial/geographic differences as well as differences in study design, diagnostic criteria and methods of reporting, among others. The estimated incidence rate in Europe is 0.4-2.8 × 10 5 /year for PV, 0.38-1.7 × 10 5 /year for ET and 0.1-1 × 10 5 /year for PMF [2] . There are few reliable estimates of the prevalence [2, 3] . The last is likely to be rising due to earlier diagnosis and trends towards prolonged survival [4] . The reported median age at diagnosis ranges from 65-74 years for PV, 64-73 years for ET, and 69-76 years for PMF [2] . diagnosis and pathology/molecular biology To achieve the most accurate diagnosis possible, the 2008 WHO classification is recommended. It is based upon standardised morphological features, ideally using specimens obtained before treatment, and is integrated with haematological, molecular and clinical diagnostic criteria (Table 1) . For full details and images of classical morphological features, the reader is referred to the WHO publication [1] . European consensus-based criteria for grading of cellularity and bone marrow (BM) fibrosis should be followed (Table 2 ) [6] .
In PV, classical BM features are a moderate to overt increase in age-matched cellularity, due to a trilineage proliferation ( panmyelosis) of erythroid and granulocytic precursors and megakaryocytes in variable proportions. Megakaryocytes are characterised by a pleomorphic appearance due to the variability in sizes, from small to giant cells, without gross abnormalities of maturation. There may be minimal (grade 1) reticulin fibrosis, which is very rarely grade 2.
In ET, age-adjusted cellularity is normal or sometimes slightly increased; there is no left-shifted neutrophil granulopoiesis. Any case with a mild to moderate panmyelosis is suspicious for early PV rather than ET. Megakaryocytes have increased in number and are randomly distributed within the BM, with scattered forms or a few loose clusters. Large to giant mature megakaryocytes with extensively folded (staghorn-like) nuclei and mature cytoplasm are in the majority. Gross disturbances of the histologic topography or extensive dense clustering of megakaryocytes should not be detectable. There is no substantial increase of reticulin fibres. The WHO classification suggests that these features clearly distinguish ET from pre-fibrotic/early PMF; however, minor diagnostic criteria should also be present in order to assign this diagnosis (Table 1) .
In the initial phases of PMF, the BM is often hypercellular with prominent granulocytic and megakaryocytic proliferation, frequently with a reduction of erythroid precursors. If reticulin fibrosis is present, grade 1 is allocated. Megakaryopoiesis is characterised by the extensive formation of loose to dense clusters of megakaryocytes, with abnormal localisation toward the endosteal borders. Megakaryocyte anomalies include a high degree of cellular atypia (from small to giant forms), abnormal nuclear folding and an aberrant nuclear cytoplasmic ratio created by large, bulbous and hyperchromatic cloud-shaped nuclei. Naked (bare) megakaryocytic nuclei are often visible.
Overall, the megakaryocytes in PMF show a more pronounced degree of atypia than in other MPN subtypes. The more advanced fibro-osteosclerotic phases of PMF are characterised by grade ≥2 reticulin deposition, and the appearance of coarse bundles of collagen fibres. Additional features include endophytic bone formation (osteosclerosis) associated with extension of adipose tissue. Dilated marrow sinuses with intraluminal haematopoiesis, especially made up of megakaryocytes, are often seen.
The morphological hallmark of post-polycythaemia vera myelofibrosis (PPV-MF) and post-essential thrombocythaemia myelofibrosis (PET-MF) is overt reticulin and collagen fibrosis of the BM. Cellularity varies, but hypocellularity is common.
Clusters of megakaryocytes (often with hyperchromatic and abnormal nuclei) are prominent, while erythropoiesis and granulopoiesis are decreased. Osteosclerosis may occur. However, these findings must be integrated with other features to achieve a diagnosis (Table 3) .
Although a number of clinicopathological studies have demonstrated that a reliable morphological differentiation can be achieved with high consensus rates [8] [9] [10] , both the reproducibility and the clinical usefulness of the WHO classification of MPNs remain controversial issues, especially concerning the distinction between ET and pre-fibrotic/early myelofibrosis (MF) as well as initial cases of PV from ET or even PMF [11, 12] . To avoid incorrect classification, comprehensive evaluation and, if necessary, re-evaluation of patients are suggested. This also ensures that the patient is not unnecessarily diagnosed as 'MPN-unclassified'.
MPNs are characterised by somatic recurrent mutations and are included as the main criteria in the 2008 WHO classification (Table 1) , for which a further revision is expected in the future due to the newly discovered calreticulin (CALR) mutations [5] . These mutations include the Janus kinase (JAK) 2V617F mutation, found in ≥95% of PV and ∼60% of ET and PMF patients. 3%-5% of ET and 5%-8% of PMF patients have point mutations at codon 515 of the gene encoding the thrombopoietin receptor MPL (W>L, K or A).
Abnormalities (deletions/duplications/substitutions) located in exon 12 of JAK2 are detected exclusively in 2%-4% of PV. About 60%-80% of JAK2 and MPL un-mutated patients with ET and PMF have mutations in the exon 9 of CALR. Therefore, virtually all patients with PV have a mutation in JAK2.
Conversely, 10%-15% of ET and PMF patients remain molecularly uncharacterised, and are operationally defined as 'triple negative' for the three phenotypic driver mutations. The presence of any of these mutations excludes reactive forms of erythrocytosis, thrombocytosis and MF, but does not indicate a specific MPN subtype. These mutations can be found using methods such as conventional sequencing, qualitative and quantitative polymerase chain reaction (PCR) and high-resolution melting analysis (may have a sensitivity of 1% and higher). Whole blood or purified granulocytes are harvested and tested; the latter is preferred in cases with low mutation burden, as is often the case with JAK2 exon12 mutations. Genotyping should be obtained at diagnosis. It is not recommended to measure the mutation burden serially during follow-up or to assess response to treatment, except following allogeneic stem-cell transplantation (alloSCT) and, possibly, interferon (IFN) treatment. In such instances, a detection limit of JAK2V617F allele burden of ≤0.1% is recommended [13] .
achieving an accurate diagnosis Table 1 should be followed strictly [1] . Any patient with suspected MPN should be tested for the three driver mutations [I, B] . A simplified diagnostic algorithm is presented in Figure 1 . A diagnosis of PPV-MF or PET-MF is made using the criteria described by the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT) ( Table 3) .
assessment of prognosis
Any patient newly diagnosed with MPN should be categorised at baseline according to the risks associated with the disease [I, B]. It must be realised that the prognostic scoring systems used for risk-adapted therapy in PV and ET are based on the likelihood of patients developing thrombotic complications. These complications are the leading cause of morbidity and mortality in PV and ET patients. Scores predicting for overall survival in PV and ET are also available, yet considering the long survival of these disorders, they do not currently impact treatment decisions [14, 15] . The recommended prognostic scoring system for PV and ET is based upon two variables: age >60 years and previous history of thrombosis. These variables separate patients into low-or highrisk categories (Table 4) . In ET, an intermediate-risk group is sometimes advocated. However, this group is variably defined and there is no clear evidence of how to manage patients in this category. Thrombocytosis (>1000 × 10 9 /l) is a risk factor for haemorrhage, and advocates caution for the use of aspirin. Extreme thrombocytosis (>1500 × 10 9 /l) is regarded as an indication for therapy in ET, and less frequently in PV. Improved risk stratification is desirable, but any new risk stratification should be robust, easily measurable and ideally validated in a prospective manner.
Since the median survival in PMF is ∼6 years, ranging from <2 to >10 years, the relevant end point for current prognostic scoring systems in PMF is represented by survival ( Table 5 ). The International Prognostic Scoring System (IPSS) [18] is used at the time of diagnosis to outline four risk categories (low, intermediate-1, intermediate-2 and high risk), with median survival of 135, 95, 48 and 27 months, respectively. The 'dynamic' IPSS [19] , which utilises the same variables as the IPSS, is employed during follow-up. A refinement is represented by DIPSS-plus score [20] that incorporates thrombocytopaenia, transfusion requirements and abnormal cytogenetics ( Table 5 ). The role of CALR [21] and other mutations (i.e. EZH2, ASXL1, SRSF2, IDH1/2 mutations), comprising a high-molecular risk category in PMF [22] , has been underscored but has yet to be incorporated in an updated prognostic score. Appropriate risk stratification in PMF has relevance for risk-adapted therapy, particularly for alloSCT. These scores are commonly used for PPV-MF and PET-MF. It should be underlined that they have not been validated in such a context, and their appropriateness has been questioned [23] .
management
Treatment aims are to reduce the risk of thrombosis and haemorrhage, control symptoms and perhaps reduce the risk of progression ( Figure 2 ). Cure is not presently possible, except in selected MF patients who are successfully receiving alloSCT. All patients should be informed regarding the disease course, and vascular risk factors such as smoking should be aggressively managed.
polycythaemia vera PV therapy should address both short-and long-term objectives ( Figure 2A ). In the short-term, therapeutic aims are to reduce the risk of occurrence and recurrence of thrombosis. The longterm objective is to reduce the risk of evolution to MF, myelodysplastic syndrome (MDS) and/or acute myeloid leukaemia (AML) [16] . Risk stratification (Table 4) aims at selecting the patients with a low risk of vascular events. PV is associated with elevated haematocrit (HCT); with these patients, phlebotomy is carried out to control the HCT and low-dose aspirin is used, as it may delay the need for cytoreductive therapy.
first-line therapy. Phlebotomy can be an emergency therapy at diagnosis, in patients presenting with very high HCT and clinical signs of hyperviscosity, as well as a long-term maintenance Table 5 . Risk stratification in primary myelofibrosis (MF)
Variable
IPSS [18] DIPSS [19] DIPSS-plus [20] Age >65 years [16] . HU is a wellknown cytoreductive agent, with good efficacy and tolerance in the majority of patients. In the unique randomised trial comparing HU with another cytoreductive drug ( pipobroman) in PV, the cumulative incidence of AML/MDS at 10, 15 and 20 years was 6.6%, 16.5% and 24% in the HU arm and 13%, 34% and 52% in the pipobroman arm, respectively (P = 0.004) [26] . Other studies from registry data and prospective analysis with shorter follow-up failed to attribute a clear leukaemogenic risk to HU [17, 27] . Overall, there is no definitive evidence for (or against) a leukaemogenic risk of HU, but it should be emphasised that this risk may appear after prolonged exposure to this drug. Thus, it seems reasonable to adopt a conservative approach and to consider alternative treatments in young subjects, and in those previously treated with other myelosuppressive agents. IFN-α has been shown to induce a high rate of haematological response and to significantly reduce the malignant clone, as shown by the percentage of mutated allele JAK2V617F in two phase II studies [28, 29] . However, this drug (in any of its various presentations) is not approved for the treatment of PV. Two phase III studies comparing HU to pegylated forms of IFN-α are ongoing in the United States and Europe. These studies should help to better define the efficacy and tolerance of each drug in the short term [30] . Whenever possible, patients should be recruited into these studies [II, B] . Aquagenic pruritus is a disabling symptom in some PV patients: IFN-α or JAK2 inhibitors can be used to treat this symptom. Other options include antihistamines, selective serotonin reuptake inhibitors and PUVA ( psolarens + ultraviolet A) therapy [IV, B] [31, 32] .
second-line therapy. The choice of second-line myelosuppressive drugs for PV should be carefully evaluated because some drugs administered after HU may enhance the risk of acute leukaemia [II, B] [33] . Finally, in selected patients, alkylating agents like busulfan may be useful when other drugs have failed or are contraindicated, although they are characterised as inducing an increased leukaemogenic risk [III, C] [16] . In PV, a phase III study showed the use of ruxolitinib was superior, compared with the best available therapy, to control HCT and splenomegaly in PV patients who are resistant or intolerant to HU. These results suggest that ruxolitinib could be a new option as a second-line therapy in PV [I, A] [34] .
essential thrombocythaemia
Aspirin in ET has never been evaluated in a randomised, controlled trial, and there is a concern that bleeding is a particular risk for ET patients with extreme thrombocytosis (>1000 × 10 9 /l) [35] . Low-dose aspirin is recommended in the setting of highrisk ET patients without a clear contraindication to this therapy [III, B] . For low-risk ET patients, a retrospective analysis suggested that only those who are either JAK2V617F-positive or have cardiovascular risk factors may benefit from anti-platelet therapy [36] . Pending further data, we recommend low-dose aspirin for low-risk ET patients, since thrombosis remains the major clinical hazard [III, B] ( Figure 2B ).
The choice of the most appropriate first-line cytoreductive therapy for high-risk ET is based on three randomised trials [37] [38] [39] . There is a debate regarding whether HU, anagrelide or IFN-α should be the treatment of choice. In addition, there is an increased interest in 'pegylated' forms of IFN. HU versus no myelosuppressive therapy significantly reduced the rate of thrombosis in high-risk ET patients, most of whom received anti-platelet prophylaxis with aspirin or ticlopidine [37] . The use of anagrelide versus HU has been evaluated in the PT-1 study and the non-inferiority ANAHYDRET study. Anagrelide was equivalent to HU in reducing platelet counts in both studies. In the PT-1 study, an excess of arterial thrombosis was seen in the anagrelide arm compared with HU [38] . However, in the ANAHYDRET, study equivalence was reported [39] . The use of HU and low-dose aspirin as first-line therapy for highrisk ET is recommended, but in specific groups of patients, IFN or sometimes anagrelide may be appropriate [I, B] . Whenever possible, patients with ET should be enrolled in randomised studies evaluating HU compared with IFN. According to current label approvals in Europe, anagrelide may be used as second-line therapy for patients who are resistant or intolerant to HU. IFN or busulfan are also options available in this setting. The use of cytotoxic agents, in the youngest patients and/or especially in combination, should be avoided where possible [III, B] . In the presence of extensive thrombocytosis (>1.500 × 10 9 /l), the benefits of anti-platelet agents should be balanced against the risks of haemorrhages due the occurrence of acquired von Willebrand disease [35] .
myelofibrosis
Since there is no curative therapy other than alloSCT for PMF and PPV-/PET-MF, treatment is essentially palliative and is generally guided by the predominant symptoms, anaemia and splenomegaly ( Figure 2C ).
anaemia. A haemoglobin <10 g/dl usually triggers consideration of treatment, but there are individual variations depending upon age and comorbidities. One of the first options is erythropoiesis-stimulating agents, which produce improvements in 23%-60% of patients [40, 41] . Response is often restricted to patients with inadequate erythropoietin levels (<125 mU/ml), and less frequently when there is significant splenomegaly or transfusion dependence. If no response is obtained at three JAK inhibitors. The JAK inhibitors act mainly by inhibiting dysregulated JAK-STAT signalling, present in all MF patients. They are not selective of the mutated JAK2; therefore, they are indicated in both JAK2-mutated and JAK2-unmutated MF. Ruxolitinib, an oral JAK1/JAK2 inhibitor, is the first in-class drug approved for MF treatment [50] . Thrombocytopaenia is a main adverse event observed with JAK inhibitors, and worsening anaemia is often seen, especially at the beginning of therapy. These drugs are also associated with an increased risk of infection. Spleen reduction and symptom control are usually dramatic but are also drug-and dose-dependent.
It has been reported that sudden ruxolitinib withdrawal can provoke a shock-like syndrome, due to the re-emergence of the suppressed inflammatory cytokines [51] . Though this side-effect is rare, abrupt interruption should be avoided and withdrawal of the drug should be tapered.
Two phase III studies compared ruxolitinib with placebo (COMFORT-I) [52] or best available therapy (COMFORT-II) [53] ; both attained the primary end point of ≥35% reduction in spleen volume by imaging techniques at 24 or 48 weeks of treatment, respectively [I, A]. The effect on JAK2V617F allele burden was modest [54] . A survival advantage for patients treated with ruxolitinib was first shown from historical comparison with matched MF populations [55, 56] . Extended follow-up of the phase III studies indicated a survival advantage for patients on ruxolitinib [54] . However, there is little evidence of a diseasemodifying effect. Other JAK inhibitors are currently being studied in clinical trials, although several trials have been withdrawn due to emergent neurological toxicity. The precise mechanism for this toxicity is unclear but merits close monitoring.
stem-cell transplantation. AlloSCT is currently the only curative treatment approach for MF, resulting in resolution of BM fibrosis, molecular remission and restoration of normal haematopoiesis [57, 58] . Depending on the disease status, patient's performance status, comorbidities and donor availability, ∼40%-70% of patients can be cured [57, 58] . Careful patient selection is mandatory, due to the inherent risks of alloSCT. Patients with PV or ET are not candidates for alloSCT, unless their disease has transformed into MF or secondary acute leukaemia [59] . Results with completely matched, related and unrelated donors are superior to those with human leukocyte antigen-mismatched donors [57, 60] . Reduced-intensity conditioning regimens resulting in lower therapy-related complications have broadened the availability of alloSCT to older patients, but a direct comparison to standard myeloablative conditioning is lacking [57, 59] . According to ELN recommendations, it is justified to offer alloSCT to eligible patients with MF whose median survival is expected to be <5 years. This includes patients with intermediate- 
personalised medicine
MPNs are diseases that typically affect people within a midadvanced age group. Therefore, any treatment decisions, especially regarding thrombosis prevention and selection of patients for alloSCT, should consider the patient's general condition and comorbidities. The diagnostic approach has improved remarkably with the discovery of recurrent phenotypic driver mutations, but there is still a need for standardised and validated mutational tests. The interpretation of BM histopathology features, as required by the current WHO classification, requires experienced pathologists, particularly for the differential diagnosis of early and/or for mutation-negative cases.
There are a number of prognostic scores that are useful for guiding treatment, yet they have been built on retrospective clinical practice guidelines Annals of Oncology series and are not validated prospectively, nor in the settings of conventional or new therapies. This is a challenge of particular relevance today, when novel targeted drugs are being used in clinical trials, and the first in-class JAK inhibitor has been approved. However, in spite of these recent advancements, we have to acknowledge that there are still too few effective treatment options for highly heterogeneous diseases such as MPNs, which additionally show high degrees of variability from patient to patient. In this disease setting, more research is needed to identify molecular markers which could lead to advances in personalised medicine.
long-term follow-up and response evaluation
In patients with asymptomatic and well-controlled PV, followup visits can be scheduled at 2-4 month intervals to determine phlebotomy needs; in those with high-risk PV receiving stable HU dosage and/or IFN with very infrequent/absent phlebotomy needs, a 4-to 6-month interval may be appropriate. In low-risk ET patients, a visit at the 6-to 12-month interval is sufficient, while for those with high-risk ET receiving cytoreduction, a 3-to 4-month interval is recommended. Clinical and laboratory evaluation should be more frequent in the initial phases of disease management until a stable phlebotomy rate and/or drug dose is achieved. Most patients maintain their HU dose steadily for several years, although in a minority of patients, excessive myelosuppression may develop that requires dose adjustment. Routine chemistry assessment (including at least lipid panel, glucose, renal and hepatic function tests) is recommend at 1-year intervals. While an ultrasound scan of the abdomen is suggested at first visits to exclude subclinical splanchnic vein thrombosis or spleen infarcts, assessment of splenomegaly can be conveniently carried out by palpation at each follow-up visit. Unless there is a suspicion of disease progression to post-PV/post-ET MF, there is no indication to Table 6 . Criteria for assessing response to treatment in polycythaemia vera (PV) and essential thrombocythaemia (ET) according to the ELN criteria Table 7 . Criteria for assessing response to treatment in PMF according to the IWG-MRT and ELN criteria [63] Response categories Required criteria (benefit must last >12 weeks to qualify as a response)
Complete remission (CR) Bone marrow: age-adjusted normal cellularity; <5% blasts; ≤grade 1 fibrosis, and Peripheral blood: Hb ≥100 g/l, and <UNL; neutrophil count ≥1 × 10 9 /l and <UNL;
Platelets ≥100 × 10 9 /l and <UNL; <2% immature myeloid cells, and Clinical: resolution of disease symptoms; spleen and liver not palpable; no evidence of EMH Partial remission (PR) Peripheral blood: Hb ≥100 g/l, and <UNL; neutrophil count ≥1 × 10 9 /l and <UNL; platelets ≥100 × 10 9 /l and <UNL; <2% immature myeloid cells, and
Clinical: resolution of disease symptoms; spleen and liver not palpable; no evidence of EMH, or Bone marrow: age-adjusted normal cellularity; <5% blasts; <grade 1 fibrosis, and Peripheral blood: Hb ≥85 g/l but <100 g/l and <UNL; neutrophil count ≥1 × 10 9 /l and <UNL; platelets ≥50 × 10 9 /l but <100 × 10 9 /l and <UNL; <2% immature myeloid cells, and
Clinical: resolution of disease symptoms; spleen and liver not palpable; no evidence of EMH Clinical improvement (CI) The achievement of anaemia, spleen or symptom response without progressive disease or increase in severity of anaemia, thrombocytopaenia or neutropaenia Anaemia response Transfusion-independent patients: a >20 g/l increase in haemoglobin level Transfusion-dependent patients: becoming transfusion-independent Spleen response A baseline splenomegaly that is palpable at 5-10 cm below the LCM becomes not palpable, or A baseline splenomegaly that is palpable at >10 cm below the LCM decreases by ≥50% A baseline splenomegaly that is palpable at <5 cm below the LCM is not eligible for spleen response A spleen response requires confirmation by MRI or CT showing ≥35% spleen volume reduction Symptom response A ≥50% reduction in the MPN-SAF TSS Progressive disease Appearance of a new splenomegaly that is palpable at least 5 cm below the LCM, or A ≥100% increase in palpable distance below LCM for baseline splenomegaly 5-10 cm, or A 50% increase in palpable distance below LCM for baseline splenomegaly of >10 cm, or Leukaemic transformation confirmed by a bone marrow blast count of ≥20%, or A peripheral blood blast content of ≥20% associated with an absolute blast count of ≥1 × 10 9 /l that last for at least 2 weeks
Stable disease Belonging to none of the above response categories Relapse No longer meeting criteria for at least a CI after achieving CR, PR or CI, or Loss of anaemia response persisting for at least 1 month, or Loss of spleen response persisting for at least 1 month Cytogenetic remission At least 10 metaphases must be analysed for cytogenetic response evaluation and requires confirmation by repeat testing within a 6-month window CR: eradication of a pre-existing abnormality PR: ≥50% reduction in abnormal metaphases (PR applies only to patients with at least 10 abnormal metaphases at baseline) Molecular remission Molecular response evaluation must be analysed in peripheral blood granulocytes and requires confirmation by repeat testing within a 6-month window CR: eradication of a pre-existing abnormality PR: >50% decrease in allele burden (partial response applies only to patients with at least 20% mutant allele burden at baseline) Cytogenetic/molecular relapse Re-emergence of a pre-existing cytogenetic or molecular abnormality that is confirmed by repeat testing Grading of fibrosis is according to European scale (see Table 2 ). Transfusion dependency before study enrolment is defined as transfusions of at least 6 units of packed red cells (PRBC), in the 12 weeks before study enrolment, for a haemoglobin level of <85 g/l, in the absence of bleeding or treatment-induced anaemia. In addition, the most recent transfusion episode must have occurred in the 28 days before study enrolment. Response in transfusion-dependent patients requires absence of any PRBC transfusions during any consecutive 'rolling' 12-week interval during the treatment phase, capped by a haemoglobin level of ≥85 g/l. Spleen or liver responses must be confirmed by imaging studies where a ≥35% reduction in spleen volume, as assessed by MRI or CT, is required. Furthermore, a ≥35% volume reduction in the spleen or liver, by MRI or CT, constitutes a response regardless of what is reported with physical examination. MPN-SAF TSS, MPN symptom self-assessment form total symptom score. This is assessed by the patients themselves and includes fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss and fevers, which are ranked each from 0 (absent/as good as it can be) to 10 (worst imaginable/as worst as it can be); the TSS is the summation of all individual scores (0-100 scale supported by clinical trials but may be appropriate considering a rate of thrombosis (fatal and non-fatal) of 1.75%, comparable with ET [64] . In patients who have already experienced major cardiovascular events, prevention of recurrence should be carried out according to general lines of management, depending on the type and site of previous thrombosis. In patients with splanchnic vein thrombosis or recurrent venous thrombosis and pulmonary embolism, lifelong oral anti-coagulation is usually suggested, although there is debate among experts in the absence of controlled studies [65] . The use of new anti-coagulants in these specific settings has not been evaluated yet. Indications for special situations are described below.
resistance or intolerance to first-line cytoreductive agents: The phenomenon of HU resistance or intolerance, as defined by the ELN (Table 8) , is important. It identifies a group of ET or PV patients with a poor prognosis [70, 71] , who require a change of treatment, and for whom novel therapies such as JAK inhibitors may be attractive. We recommend options for management that include (in the face of HU resistance or modest intolerance): reducing the dose by adjusting therapeutic targets (e.g. raising the platelet count target to 600 × 10 pregnancy: Current literature for pregnancy outcomes in MPN is sparse and likely to be subject to reporting bias. ET is the most common MPN in women of childbearing age. Maternal morbidity is uncommon in ET, but has been reported. Successful pregnancy occurs in up to 70% of patients. The literature regarding PV and MF, while very limited, is concordant with pregnancy outcome in ET. The suggested management of pregnancy in MPN derives mainly from a few single-centre studies [III, B] [75] . Disease management should be optimised before conception. HU and anagrelide should be stopped with an adequate wash-out period. If cytoreductive therapy is needed, IFN should be considered. Depending on the risk assessment results, women should be managed according to a standard-risk or highrisk pregnancy protocol, with multidisciplinary review. Unless contraindicated, all women should receive low-dose aspirin throughout pregnancy. For women with PV, venesection can be continued to maintain HCT levels within a gestation-appropriate target range, and is sufficient for standard-risk pregnancy. For high-risk pregnancy, i.e. if one (or more) of the factors in Table 9 is present or is likely to occur during pregnancy, additional treatment including cytoreductive therapy with IFN and low molecular weight heparin (LMWH) may be considered.
Foetal monitoring is suggested during pregnancy; scans should be carried out at 20, 26 and 34 weeks. Uterine artery Doppler should be carried out at 20 weeks. In the presence of a mean pulsatility index >1.4, the pregnancy may be considered high risk and treatment can be escalated, along with additional growth scans, as appropriate.
Local protocols with regard to interruption of LMWH should be adhered to during labour, and dehydration should be avoided. Postpartum LMWH thromboprophylaxis for 6 weeks should be considered. Thrombosis has been documented in the postpartum period, and blood counts should be monitored at this time.
Breastfeeding is safe with low-dose aspirin, heparin and warfarin ( providing the new-born receives adequate vitamin K), but it is traditionally contraindicated with cytoreductive therapy. Decisions about breastfeeding while taking IFN should be made on an individual basis, after discussion regarding possible risks and benefits [III, B].
hormonal therapy: An individualised risk benefit assessment should be undertaken in considering hormonal therapy. The overall evidence grade is poor here [V] . For testosterone therapy, the major MPN-specific risk is of provoking an erythrocytosis which should be monitored. Concerning oestrogen and progesterone, the major risk is of thrombosis. In this case, topical therapies including coated intra-uterine devices are likely to be extremely low-risk and acceptable. For oral contraception, progesterone-only preparations are acceptable, but the combined oral contraceptive (i.e. both progesterone and oestrogen) is not recommended [V] . Where short-term hormonal manipulation is required, for example in fertility treatment, thromboprophylaxis should be considered and the patient should be counselled about thrombosis risk. Lastly, menopausal hormone replacement has recently been suggested to have minimal associated thrombosis Table 9 . Criteria for defining 'high risk' a pregnancy in the course of a myeloproliferative neoplasm (MPN) (adapted from [76] risk. An individual assessment weighing up the risks and need for treatment should be carried out.
surgery: Disease phenotype, individual patient variables and surgery-specific factors including choice of anaesthesia contribute to the personal risk of postoperative thrombosis and bleeding in MPN. Most of the data exist for ET patients, and arterial events are increased postoperatively at ∼3.8%, but there is also a 10.5% bleeding risk with surgery [77] . This side-effect is thought to be caused by a combination of disease-related primary platelet abnormalities, anti-platelet agents and anti-coagulant therapy. For this reason, careful preoperative review is required, with consideration given to temporary control of platelet counts (especially for procedures where there is a significant risk if bleeding occurs or when patients are at increased risk of bleeding or thrombosis, as a consequence of the procedure). The use of anti-platelet and anti-coagulants should be adjusted according to local policy. Postoperative thromboprophylaxis with LMWH is recommended. It is not necessary to extend thromboprophylaxis beyond the normal period of time postoperatively simply because of an MPN diagnosis. Controlling blood counts preoperatively to standard targets for high-risk patients should be considered in MPN patients undergoing surgery, when bleeding is a risk or when thromboprophylaxis would normally be prescribed [IV, C].
methodology
These clinical practice guidelines were developed in accordance with the ESMO standard operating procedures for clinical practice guidelines development. The relevant literature has been selected by the expert authors. Levels of evidence and grades of recommendation have been applied using the system shown in Table 10 . Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty. This manuscript has been subjected to an anonymous peer review process. 
